drugset / Trial / NCT02220907

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

NCT02220907

Phase 3 Completed 153 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.

Timeline

Start
2014-08
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Background Teneligliptin Small molecule 20 mg Oral